Most cannabis conversations start and end with two compounds: THC and CBD. They are the most abundant cannabinoids in the plant and the ones that have received the most attention from scientists and consumers alike. But cannabis produces over 100 distinct cannabinoids, and a growing body of research suggests that the lesser-known ones may play a significant role in shaping your experience with flower.
These compounds, collectively called minor cannabinoids, include CBN (cannabinol), CBG (cannabigerol), and THCV (tetrahydrocannabivarin). They are present in smaller concentrations than THC or CBD, but emerging studies indicate they each interact with the body in unique ways. For consumers in New York who want to make more informed choices at the dispensary, understanding these molecules is becoming increasingly valuable.
What Makes a Cannabinoid "Minor"?
The term "minor" simply refers to concentration. In most cannabis flower, THC and CBD dominate the chemical profile, often making up 15 to 30 percent of the plant's total weight by dry mass. Minor cannabinoids, by contrast, typically appear at levels below one or two percent. That lower concentration does not mean they are unimportant. Research increasingly suggests that minor cannabinoids contribute to what scientists call the entourage effect, the idea that cannabis compounds work together to produce effects that none of them could achieve alone.[1]
Think of it this way: if THC and CBD are the lead instruments in a band, minor cannabinoids are the rhythm section. You might not notice them individually, but they shape the overall sound. The same principle applies to terpenes, which we explored in our guide to cannabis terpenes and anxiety. Together, cannabinoids and terpenes create the full character of a strain.
CBN: The Sleepy Cannabinoid
Cannabinol, or CBN, is one of the most talked-about minor cannabinoids in the wellness space right now, particularly for its association with sleep. CBN forms naturally when THC ages and oxidizes over time, which is why older cannabis flower tends to contain higher levels of it.[2]
The sleep connection is where CBN has generated the most consumer interest. A 2023 randomized, double-blind clinical study found that participants who received 20 mg of CBN experienced reduced nighttime awakenings and overall sleep disturbance compared to those given a placebo.[3] Interestingly, the same study found that adding CBD to CBN did not improve outcomes further, suggesting that CBN may work best on its own or alongside THC rather than CBD.
A separate meta-analysis from 2025 confirmed that cannabinoid preparations containing THC and CBN were associated with improved subjective sleep quality ratings, while CBD-only preparations did not show the same effect.[4] These are early findings, and more large-scale trials are needed. But for consumers who have noticed that certain strains seem to promote deeper rest, CBN content may be part of the reason.
Beyond sleep, preliminary research suggests CBN may also have analgesic and anti-inflammatory properties.[5] A 2023 study published in the journal Molecules found that CBN, along with CBC and THCV, demonstrated the ability to reduce markers of inflammation in human immune cells.
CBG: The Mother Cannabinoid
If you want to understand where cannabinoids come from, start with CBG. Cannabigerol's acidic precursor, CBGA, is the chemical starting point from which the cannabis plant synthesizes THC, CBD, CBC, and virtually every other cannabinoid as it matures. This is why CBG is often called the "mother" or "stem cell" cannabinoid.[6]
Because the plant converts most of its CBGA into other cannabinoids during growth, mature cannabis flower usually contains very low levels of CBG. Breeders are now developing CBG-rich cultivars harvested at earlier stages to preserve higher concentrations.
The research on CBG is still in its early stages, but the preliminary findings are notable. A 2025 study demonstrated that CBG's anti-inflammatory effects worked through a specific cellular signaling pathway (JAK/STAT/NFkB) and effectively reduced symptoms resembling atopic dermatitis in animal models.[7] Separate research has investigated CBG for potential applications in inflammatory bowel conditions and glaucoma, though human clinical trials remain limited.
What makes CBG particularly interesting for cannabis consumers is its non-intoxicating nature. It does not produce a high on its own, but in full-spectrum flower, it may contribute to the overall experience by interacting with CB1, CB2, and TRP receptors in the body's endocannabinoid system.[8]
THCV: The Clear-Headed Cousin of THC
Tetrahydrocannabivarin, or THCV, looks almost identical to THC on a molecular level. The only structural difference is a shorter side chain, but that small change significantly alters how the compound behaves in the body.
At low doses, THCV appears to act as an antagonist at CB1 receptors, meaning it may block some of the effects typically associated with THC, such as appetite stimulation. This is a reversal of what most people expect from cannabis, and it is why early research has explored THCV for potential metabolic benefits. Studies suggest it may help regulate blood sugar levels and reduce insulin resistance, though this work has been conducted primarily in animal models and cell cultures rather than large human trials.[9]
At higher doses, THCV may flip its behavior and begin activating CB1 receptors, producing a shorter and reportedly more clear-headed experience compared to THC. Consumers who have tried THCV-rich strains often describe the effect as focused and energetic without the heaviness that some THC-dominant flower can produce.
THCV is most commonly found in strains with African sativa heritage, though selective breeding is making it more available. It remains relatively rare in the New York market, but as cultivators continue to expand their genetic libraries, expect to see more THCV-forward options at licensed dispensaries in the coming years.
Quick Comparison
| CBN | CBG | THCV | |
|---|---|---|---|
| Source | THC degradation | Precursor to all cannabinoids | Specific genetics |
| Intoxicating? | Minimally | No | Dose-dependent |
| Key research areas | Sleep, pain | Inflammation, gut health | Metabolism, focus |
| Found in flower? | Yes, especially aged flower | Yes, in small amounts | Yes, in certain strains |
Why This Matters When You Shop for Flower
Understanding minor cannabinoids is not just academic. It can change how you approach your next visit to the dispensary. When you look at a strain's lab results and see trace amounts of CBN, CBG, or other minor cannabinoids alongside the THC and CBD percentages, you are looking at a more complete picture of what that flower will do.
This is the practical side of the entourage effect. Two strains might both test at 25 percent THC, but if one has a richer minor cannabinoid profile and a more complex terpene mix, the experiences they deliver could be meaningfully different. As we discussed in our indica vs. sativa vs. hybrid guide, the label on the jar is just the starting point. The chemistry underneath is what shapes how you feel.
At Greenline Apothecary, our flower is crafted with the full spectrum in mind. Every strain in our menu is selected to develop its complete chemical profile, not just to hit a THC number. That means preserving the terpenes, the minor cannabinoids, and the nuances that make each cultivar distinct.
The Research Is Still Early
It is worth emphasizing that much of the research on minor cannabinoids is preliminary. Many of the most promising findings come from cell studies and animal models, not large-scale human clinical trials. The 2026 landscape includes over 70 published cannabis-related studies covering everything from pain relief to metabolic health to wound healing, but definitive conclusions for most minor cannabinoids remain years away.[10]
What we can say is that the scientific community is paying closer attention to these compounds than ever before. Clinical trials at institutions including Johns Hopkins, UC San Diego, and UCLA are actively investigating cannabinoids beyond THC and CBD, and New York's regulated market means that consumers here have access to lab-tested products with transparent cannabinoid profiles.
As always, cannabis affects everyone differently. If you are exploring strains for specific wellness goals, start low, take notes on what works for you, and use lab data as a guide rather than a guarantee.
Frequently Asked Questions
What are minor cannabinoids?
Minor cannabinoids are compounds found in cannabis in smaller concentrations than THC and CBD. The most studied minor cannabinoids include CBN (cannabinol), CBG (cannabigerol), and THCV (tetrahydrocannabivarin). Each has a unique chemical structure and interacts with the body's endocannabinoid system in distinct ways, contributing to what researchers call the entourage effect.
What is CBN and what does it do?
CBN (cannabinol) forms naturally as THC ages and oxidizes over time. Early clinical research suggests CBN may support sleep quality, with one study finding that participants who received 20 mg of CBN experienced fewer nighttime awakenings compared to those given a placebo. CBN is roughly ten times less potent than THC at CB1 receptors, meaning it produces minimal intoxicating effects on its own.
What is CBG and why is it called the mother cannabinoid?
CBG (cannabigerol) is called the mother cannabinoid because its acidic precursor, CBGA, is the chemical starting point from which the cannabis plant synthesizes THC, CBD, and other cannabinoids as it matures. CBG itself is non-intoxicating. Preliminary research suggests it may have anti-inflammatory and neuroprotective properties, and it is being investigated for potential applications in conditions involving inflammation and digestive health.
What is THCV and how is it different from THC?
THCV (tetrahydrocannabivarin) is structurally similar to THC but with a shorter molecular side chain, which changes how it interacts with cannabinoid receptors. At low doses, THCV may actually block CB1 receptors rather than activate them, which is why early research suggests it could play a role in appetite regulation and metabolic health. At higher doses, THCV may produce a shorter, more clear-headed effect compared to THC.
Do minor cannabinoids get you high?
Most minor cannabinoids are non-intoxicating or produce very mild effects on their own. CBG is non-intoxicating, CBN is roughly ten times less potent than THC, and THCV at low doses may not produce noticeable psychoactive effects. However, in full-spectrum cannabis flower, minor cannabinoids work alongside THC, CBD, and terpenes to shape the overall experience through the entourage effect.
References
- Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis. Frontiers in Plant Science. 2019;9:1969. doi:10.3389/fpls.2018.01969
- Maioli C, Mattoteia D, Catanzaro M, et al. Cannabinol: history, syntheses, and biological profile of the greatest "minor" cannabinoid. Plants. 2022;11(11):1396. doi:10.3390/plants11111396
- Corroon J, Gallegos SF, Ramirez G. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Journal of Cannabis Research. 2023;5:40. PubMed:37796540
- Sleep Foundation. CBN for sleep: what the research says. sleepfoundation.org
- Formato M, Guiliano M, Ferraro S, et al. Anti-inflammatory effects of minor cannabinoids CBC, THCV, and CBN in human macrophages. Molecules. 2023;28(18):6487. PMC:10534668
- Deiana S. Potential medical uses of cannabigerol: a brief overview. Handbook of Cannabis and Related Pathologies. 2017:958-967. doi:10.1016/B978-0-12-800756-3.00115-0
- Recent 2025 study on CBG anti-inflammatory effects via JAK/STAT/NFkB signaling pathway in atopic dermatitis models. Cited in minor cannabinoid reviews.
- Navarro G, Varani K, Reyes-Resina I, et al. Cannabigerol action at cannabinoid CB1 and CB2 receptors and CB1-CB2 heteroreceptor complexes. Frontiers in Pharmacology. 2018;9:632. doi:10.3389/fphar.2018.00632
- Abioye A, Ayodele O, Marinkovic A, et al. Delta-9-tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. Journal of Cannabis Research. 2020;2:6. doi:10.1186/s42238-020-0016-7
- The Marijuana Herald. Over 70 cannabis-related studies published in 2026 highlight the diverse medical potential of cannabis. March 2026. themarijuanaherald.com